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Abstract 
Background: Increased antiretroviral therapy uptake in sub-Saharan Africa has resulted in improved survival of the 
infected. Opportunistic infections are declining as leading causes of morbidity and mortality. Though comprehensive 
data are lacking, concern has been raised about the rapid emergence of non-communicable diseases (NCDs) in the 
African HIV care setting. We therefore set out to characterise the NCD/HIV burden among adults living and ageing 
with HIV infection in Zimbabwe.
Methods: We conducted a cross-sectional study among patients receiving care in a public sector facility. We 
reviewed patient records and determined the prevalence of comorbid and multi-morbid NCDs. Associations with 
patient characteristics were evaluated using univariate and multi-variate logistic regression modelling. Significance 
testing was done using 2-sided p values and 95 % confidence intervals calculated.
Results: We recruited 1033 participants. 31 % were men. Significant gender differences included: older median age, 
more advanced disease at baseline, and greater use of stavudine and protease inhibitor containing regimens in men 
compared to women. The prevalence of comorbidity and multi-morbidity were, respectively, 15.3 % (95 % CI 13.3–
17.7 %) and 4.5 % (95 % CI 3.4–6.0 %). Women had higher rates than men of both co-morbidity and multi-morbid
ity: 21.8 vs. 14.9 %; p = 0.010 and 5.3 vs. 2.9 %; p = 0.025 respectively. The commonly observed individual NCDs were 
hypertension [10.2 %; (95 % CI 8.4–12.2 %)], asthma [4.3 % (95 % CI 3.1–5.8 %)], type 2 diabetes mellitus [2.1 % (95 % CI 
1.3–3.2 %)], cancer [1.8 % (95 % CI 1.1–2.8 %)], and congestive cardiac failure [1.5 % (95 % CI 0.9–2.5 %)]. After adjust-
ing for confounding, only age categories 45–≤55 years (AOR 2.25; 95 % CI 1.37–3.69) and >55 years (AOR 5.42; 95 % 
CI 3.17–9.26), and female gender (AOR 2.12; 95 % CI 1.45–3.11) remained significantly and strongly associated with 
comorbidity risk.
Conclusions: We found a substantial burden of comorbid non-communicable diseases among HIV infected patients 
in a high HIV and low-income setting. Integrating non-communicable diseases care, including active screening, with 
HIV care is recommended.
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Background
The successful rollout of highly active antiretroviral ther-
apy (HAART) has resulted in increased life expectancy 
of HIV infected people. However, new clinical and public 
health problems are emerging. Opportunistic infections 
and AIDS-defining cancers (ADC) which characterised 
the pre-HAART era have given way to the new challenges 
of comorbid non-communicable diseases (NCD) in those 
living and aging with HIV [1]. The health and life quality 
gains made against HIV/AIDS are now under threat from 
heart disease, diabetes, stroke, kidney and liver disease, 
(non-AIDS defining) cancers, and mental health prob-
lems which are increasingly prevalent and documented 
among the HIV positive [2]. For example, cardiovascu-
lar disease has emerged as the leading cause of morbid-
ity and mortality in HIV infected persons in developed 
country settings [3].
Inevitable age-related degenerative changes (possibly 
accelerated in HIV infection), cumulative exposure to 
antiretroviral drug toxicities, effects of ongoing inflam-
mation, progressive immune dysfunction, and long-term 
infection by the virus itself are postulated to drive these 
NCDs in HIV [4–6]. Much of what is known about HIV-
NCD comorbidities has emerged from studies in high 
income countries (HICs) [7–11]. However, the available 
sparse evidence suggests similar trends of increasingly 
prevalent NCDs among HIV infected populations in low- 
and middle-income countries (LMICs), including sub-
Saharan Africa [12, 13].
Zimbabwe’s disease terrain, similar to most SSA coun-
tries, was until recently dominated by HIV/AIDS. There 
is growing recognition, however, of the contribution 
of NCDs to the morbidity and mortality burden in the 
general population. Available limited data indicate that 
hypertension accounts for at least 40  % of all hospital 
out-patient consultations [14], while cardiovascular dis-
eases are the fourth leading cause of in-patient hospital 
mortality [15].
The only nationally representative survey [16] to 
date (2005), based on the WHO STEPwise Approach, 
reported modest prevalence of modifiable NCD risk fac-
tors. Hypertension and diabetes mellitus rates, for exam-
ple, stood at 18 and 3.7 %, respectively. With regards to 
the HIV infected population, the burden of comorbid 
NCDs remains unknown. This is despite the fact that 
HIV prevalence currently stands at 15 % in a population 
of 14 million [17].
Lack of data notwithstanding, the potential impact of 
NCD comorbidity in HIV is likely to be profound in the 
LMICs, particularly sub-Saharan Africa (SSA), which 
is home to 80  % of the global 35 million people living 
and aging with HIV [18]. There remain huge knowledge 
gaps about the epidemiology, diagnosis thresholds and 
optimal clinical management strategies of comorbid 
NCDs in HIV infection in the LMIC context. Similarly, 
there is little data on models of care appropriate to this 
phenomenon of colliding epidemics—NCDs and infec-
tions—occurring against the backdrop of fragile health 
systems and severe resource constraints [19]. Conse-
quently, the evidence base to critically inform interven-
tions and strategies to effectively meet these new and 
rapidly growing challenges in SSA is thin. Understand-
ing the NCD burden among those living and ageing 
with HIV is critical if the gains already made in the fight 
against HIV are to be maintained.
As an initial step in mapping the NCD-HIV comor-
bidity terrain in low income, high HIV burden settings, 
the study sought to describe the prevalence and pat-
terns of non-communicable disease among adults living 
with HIV infection in Zimbabwe. Additionally, the study 
investigated potential associations between prevalence 
and patterns of comorbidities with patient characteristics 
like HIV disease severity markers and exposure to differ-
ent ART drug classes.
Methods
Study setting
The study was conducted at the Mpilo HIV Clinic, an 
out-patient facility of Mpilo Central Hospital, a tertiary 
care and university teaching hospital in Bulawayo, south-
ern Zimbabwe. The clinic has been offering both adult 
and paediatric HIV care including antiretroviral therapy 
(ART) since 2004. It serves as a referral facility for other 
primary care facilities in Bulawayo and also accepts walk-
in patients. Notably, routine care in the Clinic does not 
include active screening for non-communicable dis-
eases. As a public sector facility, there are no user-fees 
for patients. To date, Mpilo HIV Clinic has nearly 12,000 
registered adult and paediatric patients with approxi-
mately 8200 being actively followed up.
Registered general nurses with additional HIV spe-
cialist training provide the bulk of ongoing clinical care. 
Doctors provide complementary care on consultation 
basis, with diagnostic support from the hospital’s labora-
tory and radiology services. Patient information is stored 
in electronic and paper-based files, and is generally linka-
ble through unique patient identifier numbers. Electronic 
records are based on FUCHIA software (Epicentre, Paris, 
France). Patient data on HIV disease stage, incident AIDS 
related and non-AIDS illnesses, prescribed drugs and 
laboratory test results are recorded at each clinic visit.
The clinic’s patient population is drawn from Bulawayo, 
Zimbabwe’s second largest city. It is an urban setting with 
a population of 800,000 and is predominantly Black Afri-
can. Bulawayo’s HIV prevalence during the period under 
review was 22  %, contrasted with the national rate of 
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15 % [17]. Zimbabwe, typical of other low-income coun-
tries undergoing transition, has an emerging epidemic of 
NCDs with available data suggesting high prevalence of 
modifiable NCD risk factors in the general population 
[16].
Study design
We conducted a cross-sectional study among patients 
receiving routine care for HIV infection. The study was 
based on records review with files sampled after patients’ 
consultations. Data on demographics, HIV disease sever-
ity markers, and antiretroviral drug history are electroni-
cally filed. Past medical history and current illnesses 
including communicable and non-communicable dis-
eases are recorded in paper-based case files. Both data 
bases, that is, the electronic and paper-based records, 
are immediately updated after every clinic visit by the 
patient.
Using a pre-designed and pilot tested data collect-
ing instrument, each patient’s files were systematically 
reviewed to detect their NCD status. Detailed clinical 
information on how individual NCD cases were diag-
nosed was not available, and hence case ascertainment 
was not possible.
Files of all patients presenting consecutively to the 
study facility for clinical review and/or drug re-supply 
during the study period (September/October 2015) were 
eligible for review. Inclusion criteria were age of at least 
eighteen (18) completed years at time of enrollment into 
the study and receiving ART at Mpilo HIV Clinic. Only 
patients registered with Mpilo HIV Clinic were eligible 
for recruitment. This is because their complete medical 
records, both electronic and paper-based, could be eas-
ily accessed from the Clinic compared to non-registered 
patients. Infected pregnant and lactating women do not 
receive their HIV care in the clinic as they attend sepa-
rate Prevention of Mother to Child Transmission of HIV 
(PMTCT) facilities and were thus automatically excluded 
from the study.
Sample size and data analysis
Based on anecdotal evidence, we estimated that the prev-
alence of co-morbidity in this population was 15 %, and 
we stated a required precision of 4 % (width of full con-
fidence interval). A sample size of 1, 225 was calculated 
to yield a 95 % confidence interval of 0.13–0.17 around a 
prevalence of 0.15. This was considered adequate preci-
sion for the study. Descriptive analyses using percentages, 
frequencies, and tabulation were undertaken. Prevalence 
of comorbidity and multi-morbidity were reported as 
proportions with 95 % confidence intervals.
Age-distribution of comorbidity/multi-morbidity were 
explored using the age categories 18–≤35, 36–≤45, 
46–≤55, and >55 years, with stratification by sex, CD4+ 
cell counts (<350 and ≥350), and ART drug class (pro-
tease inhibitor (PI) and non-PI exposure) using the x2 
test. CD4+ cell counts nearest study end date (31 Octo-
ber 2015) were used, while co-morbidity patterns across 
the individual chronic diseases were also investigated.
Univariate significance testing for factors associated 
with co-morbidity, was done using x2 tests, Wilcoxon 
rank sum tests and Kruskal–Wallis tests as appropriate, 
as well as univariate logistic regression. Two 2-sided p 
values and 95  % confidence intervals were calculated. 
The assumption of linearity in the logit model was tested 
for continuous predictors using lowess curves, and 
where the assumption was violated, continuous variables 
were categorized. Multivariable logistic regression analy-
sis was used to adjust for confounding, using a backward 
stepwise model with likelihood ratio tests. Categorical 
missing data were coded as missing and included in the 
model to ensure a complete sample size. All data were 
analysed using STATA 12.0 (StataCorp, College Station, 
TX, USA).
Study variables
The study’s main outcome variable was the prevalence of 
comorbid and multi-morbid non-communicable diseases 
among HIV infected adults. Comorbidity was defined as 
the occurrence of one non-communicable disease while 
multi-morbidity was the occurrence of at least two non-
communicable diseases. Non-communicable diseases 
of study interest were diabetes mellitus, hypertension, 
stroke, congestive cardiac failure, cancer, renal impair-
ment, asthma and chronic obstructive pulmonary disease 
(COPD).
The study also aimed to describe the distribution of 
these comorbidities and multi-morbidities according 
to additional variables including age (18–≤35, 36–≤45, 
46–≤55, >55  years), sex, CD4+ cell counts (≤350 and 
>350 cells/ml), WHO HIV disease clinical stage (I–IV), 
and lastly, ART drug class exposure and duration: these 
may have potential application in NCD comorbidity risk 
stratification algorithms.
Results
Baseline characteristics and descriptive analysis
With 1225 as the targeted sample size, a total of 1400 
consecutive adult patient’s records (>18  years old) were 
screened for eligibility over a study period of four (4) 
weeks (September–October 2015). Patients meeting 
all inclusion criteria constituted the final study sample 
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of 1033. Exclusions were patients not yet commenced 
on ART (321) and those not registered with Mpilo HIV 
clinic (46). As indicated in Table  1, the overall median 
age at study enrollment was 42 years with an interquar-
tile range (IQR) of 36–50  years. The median ages were 
46 years (IQR 39–53) for males and 41 years (IQR 35–48) 
for females. Study participants were predominantly 
female (69 %).
A total of 9658 adults on ARVs were registered with 
Mpilo HIV clinic during the study period. Similarities in 
all patient demographic and clinical characteristics were 
observed between the study participants and the popula-
tion of patients (Table  1). Notably too, the groups were 
similar in terms of their ART experience.
Study subjects generally presented for care and ini-
tiated ART with advanced HIV disease: 85  % of study 
participants had a baseline CD4+ cell count less than 
350 cells/mL. More men than women had WHO stage 
III and IV disease (56 vs. 48 %; p = 0.013), and men had 
lower CD4+ cell counts (174 vs. 202, p = 0.023) at base-
line. In terms of ART experience, approximately 80  % 
(821) of the study population had at least two (2) years 
of exposure and 56 % (559) had been on treatment for 
five (5) years or more. There were no significant gender 
differences with respect to ART experience (Table  1). 
Stavudine (D4T) containing regimens were the most 
commonly prescribed (624, 60.4  %) while protease 
inhibitor (PI)-based combinations were the least used 
(48, 4.7 %). Men were more likely to receive both D4T 
containing (67.1 vs. 57.5  %; p  =  0.001) and PI-based 
regimens (5.4 vs. 4.3 %; p = 0.001) compared to women.
Burden of comorbidity and associated factors
The overall prevalence rates of comorbidity and multi-
morbidity (Table 2) in the study population were, respec-
tively, 15.3 % (95 % CI 13.3–17.7 %) and 4.5 % (95 % CI 
3.4–6.0 %). The commonly observed prevalent NCDs, in 
order of frequency, were hypertension [10.2 %; (95 % CI 
Table 1 Characteristics of study participants and population
Variable Sample n = 1033 
(100 %)
Population n = 9658 
(100 %)
Male n = 316 
(30.6 %)
Female n = 717 
(69.4 %)
p value comparison 
between males 
and females
Sex (females), n (%) 717 (69.4 %) 6896 (71.4 %) – –
Age (years), median (IQR) 42 (36–50) 40 (37–53) 46 (39–53) 41 (35–48) <0.001
Age category (years)
 18–≤35 (n,  %) 242 (23.5) 1565 (16.2) 51 (16.2) 191 (26.7) <0.001
 35–≤45 406 (39.5) 3390 (35.1) 104 (33.1) 302 (42.4)
 45–≤55 247 (24.0) 3100 (32.1) 94 (29.9) 153 (21.4)
 >55* 134 (13.0) 1603 (16.6) 65 (20.7) 69 (9.7)
Baseline CD4 + cell count 
(cells/mL), median (IQR)
191 (104–310) 184 (85–279) 174 (95–269) 202 (108–312) 0.023
Baseline CD4+ cell count 
below 350 cells/mL 
number (%)
685 (84.6) 8654 (89.6) 212 (87.2) 473 (83.3) 0.153
Baseline WHO HIV clinical 
stage III–IV number (%)
451 (50.8) 5360 (55.5) 156 (55.5) 295 (48.8) 0.013
Duration since HIV sero-
positive state (years), 
median (IQR)
7.1 (5.4–9.2) 6.9 (5.0–9.1) 6.7 (5.1–9.3) 7.4 (5.5–9.2) 0.073
Duration of ART exposure 
(years), median (IQR)
5.3 (3.4–7.1) 5.3 (2.9–6.9) 5.2 (2.8–7.0) 5.4 (3.7–7.2) 0.234
Duration ART exposure (categorical) (years)
 <2, number (%): 182 (18.2) 1729 (17.9) 65 (21.1) 117 (16.8) 0.269
 2–5 262 (26.1) 2501 (25.9) 77 (25.0) 185 (26.6)
 >5 559 (55.7) 5302 (54.9) 166 (53.9) 393 (56.6)
ART regimen frequencies, (number,  %)
 PI-based 48 (4.7) 425 (4.4) 17 (5.4) 31 (4.3) 0.001
 D4T/3TC + EFV or NVP 624 (60.4) 5766 (59.7) 212 (67.1) 412 (57.5)
 TDF/3TC + EFV or NVP 246 (23.8) 2115 (21.9) 56 (16.1) 190 (26.5)
 AZT/3TC + EFV or NVP 115 (11.1) 1043 (10.8) 31 (9.8) 84 (11.7)
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8.4–12.2  %)], asthma [4.3  % (95  % CI 3.1–5.8  %)], type 
2 diabetes mellitus [2.1  % (95  % CI 1.3–3.2  %)], cancer 
[1.8 % (95 % CI 1.1–2.8 %)], and congestive cardiac fail-
ure [1.5 % (95 % CI 0.9–2.5 %)]. Less frequently observed 
conditions included hepatitis B liver disease, blood dys-
crasias, cardiac arrhythmias, musculoskeletal and psychi-
atric/mental health disorders, and these were collectively 
labelled as “others”.
The patterns and distribution of comorbidity and 
multi-morbidity are shown in Tables  2 and 3. Stratified 
by gender, women had higher rates of both comorbid-
ity (21.8 vs. 14.9 %; p = 0.010) and multi-morbidity (5.3 
vs. 2.9  %; p  =  0.025) relative to the men. As shown in 
Table  3, there was no difference in prevalence of indi-
vidual NCDs between the genders except for hyperten-
sion (11.7 vs. 7.0  %, p  =  0.02) and asthma (5.3 vs. 2.2, 
p = 0.026) where these conditions were more prevalent 
in females than males.
Age was another patient characteristic that dem-
onstrated statistically significant relationship with 
occurrence of both comorbidity and multi-morbidity. 
Participants aged more than 55 years had a 38 % risk of 
comorbidity and a 16  % risk of multi-morbidity. These 
risks were three (3) and forty (40) times higher, respec-
tively, than those in participants aged 18–≤35  years. 
There was no demonstrated relationship between comor-
bidity risk and baseline CD4+ cell counts. Similarly, nei-
ther was ART regimen nor ART duration associated with 
comorbidity risk (Table 4).
On univariate analysis, patient characteristics dem-
onstrating significant relationships with risk of NCD 
comorbidity were age (OR 1.05; 95  % CI 1.03–1.06), 
female gender (OR 1.59; 95  % CI 1.12–2.28), baseline 
WHO clinical stage IV (OR 1.81; 95 % CI 1.07–3.09) and 
duration of HIV infection for more than 7  years (OR 
1.59; 95  % CI 1.14–2.22). However, after adjusting for 
confounding, only age categories 45–≤55  years (AOR 
2.25; 95 % CI 1.37–3.69) and >55 years (AOR 5.42; 95 % 
CI 3.17–9.26), female gender (AOR 2.12; 95 % CI 1.45–
3.11) remained significantly and strongly associated with 
comorbidity risk (Table 4).
Table 2 Prevalence of individual NCDs, comorbidity and multi-morbidity stratified by gender
Overall Males Females p value
n Prevalence (95 % CI) n Prevalence (95 % CI) n Prevalence (95 % CI)
Comorbidity 203 19.6 (17.3–22.2) 47 14.9 (11.1–19.3) 156 21. 8 (18.8–25.0) 0.010
Multi-morbidity 47 4.6 (3.3 6.1) 9 1.8 (1.3–2.3) 38 2.7 (2.4–3.2) 0.025
Hypertension 106 10.2 (8.4–12.3) 22 7.0 (4.4–10.4) 84 11.7 (9.5–14.3) 0.020
T2DM 22 2.1 (1.3–3.2) 6 1.9 (0.7–4.1) 16 2.2 (1.2–3.6) 0.731
Asthma 45 4.3 (3.1–5.8) 7 2.2 (0.9–4.5) 38 5.3 (3.8–7.2) 0.026
Cancer 19 1.8 (1.1–2.8) 6 1.9 (0.7–4.1) 13 1.8 (1.0–3.1) 0.925
Congestive cardiac failure 16 1.5 (0.9–2.5) 3 0.9 (0.2–2.7) 13 1.8 (1.0–3.1) 0.299
Stroke 10 1.0 (0.5–1.8) 2 0.6 (0.08–2.3) 8 1.1 (0.5–2.2) 0.465
Others 39 3.8 (2.7–5.1) 9 2.8 (1.3–5.3) 30 4.2 (2.8–5.9) 0.297
Table 3 Prevalence of  co-morbidity and  multi-morbidity 
stratified by patient characteristics
Variable Co-morbidity 
prevalence (number 
of events)
Multi-morbidity 
prevalence (number 
of events)
Age groups
 18–≤35 years 12.4 (30) 0.4 (1)
 35–≤45 years 16.3 (66) 2.5 (10)
 45–≤55 years 21.8 (54) 5.7 (14)
 >55 years 38.1 (51) 16.4 (22)
 p value 0.000 0.000
Gender
 Male 47 (14.9) 2.9 (9)
 Female 156 (21.8) 5.4 (38)
 p value 0.010 0.025
Baseline CD4+ cell counts (cells/mL)
 <350 142 (20.1) 5.0 (34)
 ≥350 23 (18.3) 4.0 (5)
 p value 0.535 0.877
ART duration
 <2 years 20.1 (38) 4.4 (8)
 2–5 years 18.3 (48) 4.2 (11)
 >5 years 20.5 (115) 4.7 (26)
 p value 0.730 0.88
ART regimen
 PI-based 20.4 (10) 0.0 (0)
 D4T/3TC + EFV or 
NVP
20.3 (127) 4.8 (30)
 TDF/3TC + EFV or 
NVP
31.7 (39) 10.7 (10)
 AZT/3TC + EFV or 
NVP
23.5 (27) 3.5 (4)
 p value 0.471 0.244
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Discussion
The study set out to describe the prevalence of comorbid-
ity and multi-morbidity in a population of adults living 
with HIV infection and receiving care at a public sector 
facility in Zimbabwe. This was an initial step in under-
standing the emergent challenges of NCD comorbidity 
in HIV infection. The occurrence of these comorbidities 
and multi-morbidities was further described according 
to patient demographic and clinical characteristics. It 
is anticipated that any observed associations with these 
characteristics may help in the formulation of risk strati-
fication algorithms.
In our study, we had more female than male partici-
pants, with females presenting at a younger age and with 
less severe and/or less advanced HIV disease compared 
to their male counterparts. These findings are in keeping 
with sub-Saharan Africa’s HIV epidemic, where trans-
mission is largely heterosexual coupled with increased 
infection vulnerability of women [18], on one hand, and 
their better health-seeking behavior [20], on the other. 
We found that women were more likely to have both 
comorbidities and multi-morbidities, compared to men. 
Similarly, this pattern was observed for individual NCDs, 
notably more women had both hypertension and asthma, 
compared to men. Women also had a higher prevalence 
of T2DM than men though this relationship did not 
reach statistical significance. Though pregnant women 
were excluded from the study, the possible contribution 
of previous pregnancies to prevalent hypertension or dia-
betes mellitus was not investigated.
Meaningful comparisons across studies are precluded 
by differences in case ascertainment and the actual defi-
nitions of comorbidity. Other than findings reported 
from cohorts treated in high income countries [10, 11], 
the study by Oni et al. [21] is, to our knowledge, the only 
one from SSA that sought to address a similar research 
question as ours. In a primary care facility-based study 
in a peri-urban South African setting, they reported gen-
der- and age-stratified prevalence rates of comorbidity in 
HIV. Amongst males, comorbidity rates were 17 % (18–
34  years), 28  % (36–45  years), 34  % (46–55  years) and 
20 % (>55 years). The corresponding rates among females 
Table 4 Univariate and multivariable analyses for association between patient characteristics and comorbidity
Variable With  
comorbidity (n)
Without  
comorbidity (n)
Univariate Multivariable
OR 95 % CI p value AOR* 95 % CI p value
Age (continuous) median (IQR) 46 (40–56) 41 (35–49) 1.05 1.03–1.06 <0.001
Age category (years)
 18–≤35 30 (14.9 %)  213 (25.6 %) 1.00
 35–≤45 66 (32.8 %) 340 (41.0 %) 1.38 0.87–2.19 0.176 1.42 0.89–2.26 0.144
 45–≤55 54 (26.9 %) 194 (23.4 %) 1.98 1.21–3.22 0.006 2.25 1.37–3.69 0.001
 >55 51 (25.4 %) 83 (10.0 %) 4.36 2.60–7.32 <0.001 5.42 3.17–9.26 <0.001
Gender
 Male, no. (%) 47 (23.2 %) 269 (32.5 %) 1.00
 Female, no. (%) 156 (76.1 %) 560 (67.5 %) 1.59 1.12–2.28 0.010 2.12 1.45–3.11 <0.001
Baseline CD4+ cell count ≥500, no (%) 14 (6.9 %) 42 (5.05 %) 1.34 0.71–2.51 0.366
Latest CD4+ cell count ≥500, no (%) 91 (44.8 %) 323 (38.8 %) 1.30 0.93–1.83 0.126
Baseline WHO stage
 I 38 (21.2 %) 196 (27.4 %) 1.00
 II 49 (27.4 %) 157 (22.0 %) 1.61 1.00–2.58 0.048
 III 60 (33.5 %) 270 (37.8 %) 1.15 0.73–1.79 0.549
 IV 32 (17.9 %) 91 (12.7 %) 1.81 1.07–3.09 0.028
Duration HIV (years) ≥7 109 (53.7 %) 354 (42.6 %) 1.59 1.14–2.22 0.006
Duration ART (years)
 <2, no. (%) 38 (18.9 %) 145 (18.0 %) 1.00
 2–5 48 (23.9 %) 214 (26.6 %) 0.86 0.53–1.38 0.521
 >5 115 (57.2 %) 445 (55.4 %) 0.99 0.65–1.49 0.947
ART regimen
 D4T/3TC + EFV or NVP, no. (%) 127 (62.5 %) 498 (59.9 %) 1.00
 PI-based 10 (4.9 %) 39 (4.7 %) 1.01 0.49–2.07 0.988
 TDF/3TC + EFV or NVP 39 (19.2 %) 207 (24.9 %) 0.76 0.45–1.27 0.294
 AZT/3TC + EFV or NVP 27 (13.3 %) 88 (10.6 %) 1.20 0.75–1.93 0.444
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were 28, 30, 30 and 10 %, respectively; meaning that only 
in the younger subjects (18–45  years) was comorbidity 
higher in females than males.
Within each respective gender group, our study did 
not further stratify comorbidity according to age groups 
because of very limited events. Though this limits com-
parison with the South African findings, our study 
undoubtedly suggests lower overall prevalence of HIV-
related comorbidity. Noteworthy is the fact Oni et  al. 
included only hypertension, diabetes mellitus and TB in 
their definition of comorbidity. They reported hyperten-
sion as the commonest comorbid condition. We had sim-
ilar findings, with overall prevalence of hypertension in 
our study at 10.2 % (95 % CI 8.4–12.3).
To date, reported hypertension prevalence rates among 
HIV positive persons in SSA range from 11 % in Kenya 
[22] to 28 % in Uganda [23]. A recent systematic review 
[24] on hypertension prevalence in HIV infection and 
with a broader population focus reported rates ranging 
from 8.7 to 45.9 % in low- and middle-income countries 
(LMICs). Although we did not include an HIV negative 
comparison group in our study, our reported preva-
lence of 10.2 % is less than the previously reported Zim-
babwean national average rate of 17.9  % in the general 
population [16]. Hypertension is largely asymptomatic 
and coupled with the clinic’s lack of active screening for 
hypertension, it may be speculated that our reported low 
prevalence, relative to the general population, may repre-
sent under-diagnosis.
The literature on hypertension in HIV infected persons 
in SSA is sparse and methodological differences aside, 
findings are equivocal: some studies report higher hyper-
tension rates in the HIV positive versus the uninfected 
[25] while others suggest lower prevalence or no differ-
ences [26, 27]. Evidence from a systematic review includ-
ing predominantly non-African subjects concluded that 
the risk of hypertension among HV positive persons was 
higher in the ART experienced versus the ART-naïve. 
The review did not compare hypertension to the general 
population [28]. Interestingly, and in contrast to our find-
ings, men have been reported as being disproportionately 
affected [21].
Our study also found type 2 diabetes mellitus (T2DM) 
prevalence of 2.1 % with a higher but statistically insignif-
icant rate in females (2.2 vs. 1.9 %; p = 0.731) compared 
to males. We could not ascertain how the diagnosis of 
T2DM was made in each patient. Rates of T2DM in HIV 
higher than what we found have been reported elsewhere 
in SSA: 16  % in Kenya [29] and 23.5  % [30] in South 
Africa. A nationally representative survey of the general 
adult Zimbabwean population found T2DM prevalence 
of 3.7 % in 2005 [16]. This estimate (reported in 2005) is 
most likely outdated and unrepresentative of the current 
situation. Unpublished findings from an urban general 
population community-based survey (2012) found com-
bined rates of self-reported prevalent T2DM and previ-
ously undiagnosed hyperglycemia (random venous blood 
glucose ≥11.1 mmol/l) of nearly 9 %. A more recent esti-
mate from the WHO (2014) places T2DM (fasting glu-
cose ≥7.0 mmol/l or on medication) prevalence at 7.8 % 
(95 % CI 3.0–15.9) among adults in the general popula-
tion [31].
The relationship between HIV/ART and diabetes is 
the subject of ongoing controversy. Observations of both 
increased risk and no difference have been noted in high 
income countries [32–34]. Elevated risks are linked to, 
among other factors, duration of and exposure to certain 
ARV drugs like stavudine, efavirenz and protease inhibi-
tors [30, 34, 35]. A systemic review (2013) of the asso-
ciation between HIV/ART and development of T2DM 
in SSA subjects implied protective effects as judged by 
reduced HbA1c levels [12]. Notwithstanding lack of an 
HIV negative comparator group within our study, and 
taking into consideration sample variation, our finding 
of a 2.1 % T2DM prevalence maybe difficult to reconcile 
with, firstly, the much higher background T2DM preva-
lence in the general population, and secondly, the high 
frequency of stavudine (60.4  %), efavirenz (>60  %) and 
protease inhibitor (4.7 %) use among study participants.
In the general population hypertension and T2DM have 
similar risk factors: tobacco use, unhealthy diets, physical 
inactivity and harmful use of alcohol. These have all been 
documented to be highly prevalent in some HIV positive 
populations [36], though they were not measured in this 
study. ARV drug toxicities including lipodystrophy and 
dyslipidemias, chronic systemic inflammation, endothe-
lial dysfunction, coagulation disorders and the virus itself 
are additional risk factors peculiar to HIV disease [37].
Another finding of note was the relatively high occur-
rence of asthma in our study population. We report a 
prevalence of 4.3 % (95 % CI 3.1–5.8 %). The asthma bur-
den in the Zimbabwean general population is estimated 
at 2.3 % [38]. Female study participants had higher rates 
than their male peers (5.3 vs. 2.2 %; p = 0.026). Though 
not within the scope of the study to ascertain each 
included diagnosis, review of some patient case notes 
indicated that the diagnosis of asthma in some patients 
was based on adult-onset wheezing, effort dyspnoea and 
persistent coughing. HIV trained nurses provided the 
bulk of on-going care including initial patient assess-
ments. Pulmonary function testing was not available 
either.
Consequently, argument can be made to refer to this 
class of condition broadly as obstructive lung disease 
(OLD) [39], which includes chronic bronchitis, fixed 
airway obstruction, bronchial hyper-responsiveness as 
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well as asthma. OLD has recently come to the fore as the 
number of persons ageing with HIV continues to grow. 
Known risk factors for OLD include HIV infection, pul-
monary TB, tobacco smoking and indoor pollution from 
biomass fuel exposure [40–42]. The latter disproportion-
ately affects women in LMICs, especially SSA. Our study 
only assessed history of pulmonary TB, which stood at 
61  % among participants, and we did not measure the 
burden of the other risk factors. Asthma prevalence 
among HIV-infected persons is reported to be increased 
with possibility of a different risk factor profile from the 
uninfected population [43].
The study’s primary outcome of HIV with any comor-
bid NCD has some drawbacks. From an epidemiological 
or health systems perspective, where the concern might 
be burden of care and health resources allocation, the 
study’s end-point has currency. However, from a patho-
genesis-clinical standpoint in the given contest of HIV 
and ART exposure, the prominent limitation is that this 
end-point is potentially heterogeneous. This is because 
whereas cardiometabolic diseases like diabetes mellitus 
and hypertension may have common risk factors, other 
NCDs like asthma arguably have a different risk factor 
profile, as outlined above.
Other co-variables of study interest were ART expo-
sure, age and HIV disease severity. Overall, the study 
population had considerable ART experience with at 
least half the participants having been on treatment for 
at least 5  years. However, we found no significant rela-
tionships between either ARV drug class or duration of 
exposure with risk of comorbidity. This is in contrast 
with the accumulated evidence linking, for example, PIs 
with diabetes and cardiovascular events, or NRTIs with 
cardiac disease [12, 27, 28, 30]. CD4+ cell counts (base-
line and latest) and baseline WHO stage had no demon-
strated significant associations with comorbidity risk. 
Similarly, duration of (known) HIV sero-positive state 
was insignificant after multi-variate analysis. All these 
factors have been previously linked with comorbidity 
development [44]. Our study may have been underpow-
ered to detect these effects because of its relatively small 
sample size.
Lastly, the HIV epidemic in SAA is maturing with ever 
growing numbers of adults ageing with HIV, notwith-
standing the observation from this study of a relatively 
small proportion (13 %) being aged 55 years or more. In 
the general population, NCD risks are known to be con-
siderably increased in this age (50+ years old) group. 
Indeed, our findings point to age as being an important 
risk factor for both comorbidity and multi-morbidity in 
the HIV infected population. In multi-variate analysis 
adjusting for gender, duration of HIV sero-positive state, 
ART regimens received, and baseline WHO HIV disease 
stage and CD4 + cell counts, each additional year of age 
was associated with a 6 % increased risk of comorbidity 
(adjusted OR 1.06; 95 % CI 1.04–1.08).
Limitations
A number of limitations with our study warrant cautious 
interpretation of its findings. Firstly, as a health-facility 
based study, our inferences about the burden of comor-
bidity in the wider HIV-infected Zimbabwean adult pop-
ulation can only be guarded. A community-based study 
would have been ideal. Related to this is the second limi-
tation: selection bias. The study site is an HIV out-patient 
service of a tertiary care and teaching hospital, which 
also runs specialist medical out-patient clinics. It is likely 
that HIV positive patients with more severe comorbid 
NCDs were preferentially reviewed in the medical clinics 
inadvertently reducing the total numbers of NCD/HIV 
patients seen in the HIV clinic. In similar fashion, it is 
arguable that those with asymptomatic diseases may have 
been missed due to the lack of a policy of active NCDs 
screening. Both situations would underestimate comor-
bidity prevalence.
Disease misclassification is a possibility considering 
that the bulk of diagnoses and on-going care were nurse-
driven. Our study did not seek to validate clinical diag-
noses. We merely enumerated the diagnosed NCD cases. 
Non-infectious chronic lung diseases, for example, may 
have been misdiagnosed and treated as pulmonary TB. 
Lastly, we used routine data which is not usually col-
lected with the rigour required for research purposes. 
Though the data were sufficiently complete allowing us to 
answer our research question, more detailed data would 
have enabled additional analyses, case ascertainment 
and more robust conclusions. Lastly, inclusion of an HIV 
uninfected age- and gender-matched comparison group 
would have afforded insights into the putative roles of 
HIV and ART as drivers of NCDs.
Conclusion
In the light of these, as well as findings from other studies 
within and without SSA, it is strongly recommended that 
a policy of active screening for NCDs, especially hyper-
tension and T2DM, be adopted as part of routine HIV 
care. Due to severe resource constraints in most SSA 
care settings, targeted screening, guided by age and gen-
der for example, may be proposed. As the HIV epidemic 
increasingly overlaps with the growing problem of NCDs, 
demands for life-long care will multiply in SSA. It is high 
time to consider how the infrastructure that developed as 
a response to HIV—voluntary testing and point-of-care 
testing technologies, decentralization of treatment to pri-
mary care, public engagement and resource mobilisation, 
behavior change and social marketing strategies, among 
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others—can be adapted and simultaneously deployed in 
the fight against NCDs.
Task shifting of HIV care in SSA from doctors to nurses 
and other less skilled cadres allowed the rapid scaling of 
treatment delivery in the face of severe human capacity 
constraints. The successes notwithstanding, the training 
needs of these front line cadres may not have kept pace 
with an evolving epidemic and its emerging problems. 
Beyond the burden of NCDs in HIV, huge gaps exist in 
our knowledge of diagnosis, treatment and outcomes of 
these comorbidities within the SSA context. This is in 
turn presents urgent priorities for research.
We have shown that, in keeping with reports from 
HICs, NCD comorbidities are emerging as a significant 
and growing challenge in HIV care in SSA. The first from 
Zimbabwe, a high HIV burden country, our report con-
tributes to this growing body of knowledge of HIV and 
non-communicable diseases comorbidity. We also high-
lighted the knowledge gaps peculiar to our sub-Saharan 
African setting requiring research. Lastly, if the gains 
made in the fight against HIV are to be preserved, there 
is an urgent need to integrate NCD screening and care 
into HIV programmes.
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